TNFRSF17 and Miyoshi myopathy: Indeed, an anti-BCMA mAb, bearing triple Fc mutations (S293D:A330L:I332E) to increase the antibody-dependent cellular cytotoxicity and conjugated with a potent cytotoxic agent, monomethyl auristatin F, was tested in MM.